Loading
companiesCompany
SR One
SR One is a transatlantic biotech venture firm that began as GSK's corporate venture arm and now invests independently from London and the US West Coast. Oncology accounts for a large share of its portfolio, including Akamis Bio (gene-based immunotherapy), Avenzo Therapeutics, Charm Therapeutics (menin inhibitors for acute myeloid leukaemia) and Biotheryx (protein degradation).
Overview
SR One describes itself as 'a biotechnology venture capital firm, partnering with founders and entrepreneurs to translate innovative science into medicines', taking a 'back-and-build approach' to companies with strong fundamentals and a clearly defined development pathway. Its investing team 'is situated in key biotechnology hubs on the West Coast, USA and London, UK'; the operating entity is SR One Capital Management. Oncology is one of its portfolio filters and accounts for a large share of the companies listed: Akamis Bio (gene-based immuno-oncology for solid tumours), Ancora Biotech (biologics for oncology and inflammation), Avenzo Therapeutics (best-in-class oncology pipeline), Biotheryx (targeted protein degradation), Charm Therapeutics (menin inhibitors for acute myeloid leukaemia), Dren Bio, Effector, Fore Biotherapeutics, Simcha Therapeutics (IL-18) and Telios Pharma (blood cancers).
Portfolio (1)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Nimbus Therapeutics Boston, MA, US | Growth stage | biotech | Crossover 2023, $210M |
Notes
top- The task hint gave Philadelphia and London; the site lists West Coast USA and London, so London is used. Founding year and the GSK spin-out are not stated on fetched pages. Avenzo is already in the graph.
Similar pages
- CompanySV Health Investors
Shares Nimbus Therapeutics and the tag vc.
- CompanyAtlas Venture
Shares Nimbus Therapeutics and the tag vc.